Blue Zone Wealth Advisors LLC Has $5.12 Million Position in Veeva Systems Inc. $VEEV

Blue Zone Wealth Advisors LLC lifted its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 3.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,767 shares of the technology company’s stock after purchasing an additional 548 shares during the quarter. Blue Zone Wealth Advisors LLC’s holdings in Veeva Systems were worth $5,117,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of VEEV. Nuveen LLC acquired a new stake in shares of Veeva Systems during the first quarter worth about $365,684,000. Price T Rowe Associates Inc. MD raised its position in shares of Veeva Systems by 20.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock worth $924,754,000 after purchasing an additional 689,700 shares during the period. Linonia Partnership LP raised its position in shares of Veeva Systems by 52.7% during the first quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after purchasing an additional 633,585 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Veeva Systems by 48.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock worth $416,918,000 after purchasing an additional 585,785 shares during the period. Finally, Alliancebernstein L.P. raised its position in shares of Veeva Systems by 10.7% during the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock worth $1,273,884,000 after purchasing an additional 532,269 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Price Performance

VEEV opened at $287.04 on Friday. The business has a fifty day simple moving average of $282.91 and a 200 day simple moving average of $264.86. The company has a market capitalization of $47.05 billion, a PE ratio of 58.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.98. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). The company had revenue of $789.08 million during the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. Veeva Systems’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Equities analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Veeva Systems

In other news, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the transaction, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the business’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,665 shares of company stock valued at $7,438,000 in the last three months. Corporate insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

VEEV has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their target price on Veeva Systems from $270.00 to $300.00 and gave the company a “hold” rating in a research report on Thursday, August 28th. Wells Fargo & Company lifted their target price on Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a research report on Tuesday, August 26th. Barclays lifted their target price on Veeva Systems from $300.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. Needham & Company LLC lifted their target price on Veeva Systems from $300.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Finally, Citigroup lifted their target price on Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Sixteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $307.58.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.